DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

Search

India Globalization Capital Inc

Closed

0.3

Overview

Share price change

24h

Current

Min

0.3

Max

0.3

Key metrics

By Trading Economics

Income

632K

-1.2M

Sales

73K

330K

EPS

-0.02

Profit margin

-362.727

EBITDA

-106K

-1.7M

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

-151K

24M

Previous open

0.3

Previous close

0.3

India Globalization Capital Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 wrz 2024, 04:00 UTC

Top News

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

Peer Comparison

Price change

India Globalization Capital Inc Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About India Globalization Capital Inc

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.